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Abstract:  
Gentamicin (GEN) is an aminoglycoside antibiotic with a potent antibacterial activity against 
a wide variety of bacteria. However, its poor cellular penetration limits its use in the treatment of 
infections caused by intracellular pathogens. One potential strategy to overcome this problem is 
the use of particulate carriers that can target the intracellular sites of infection. In this study GEN 
was ion paired with the anionic AOT surfactant to obtain a hydrophobic complex (GEN-AOT) 
that was formulated as a particulated material either by the Precipitation with a Compressed 
Antisolvent (PCA) method, or by encapsulation into poly(D,L-lactide-co-glycolide) (PLGA) 
nanoparticles (NPs). The micronization of GEN-AOT by PCA yielded a particulated material with 
a higher surface area than the non-precipitated complex, while PLGA NPs within a size range of 
250-330 nm and a sustained release of the drug over 70 days were obtained by preparing the 
NPs using the emulsion solvent evaporation method. For the first time, GEN encapsulation 
efficiency values around 100% were achieved for the different NP formulations with no signs of 
interaction between the drug and the polymer. Finally, in vitro studies against the intracellular 
bacteria Brucella melitensis, used as a model of intracellular pathogen, demonstrated that the 
bactericidal activity of GEN was unmodified after ion-pairing, precipitation or encapsulation into 
NPs. These results, encourage their use for treatment for infections caused by GEN sensitive 
intracellular bacteria. 
 
Keywords: Gentamicin, hydrophobic ion pairing, supercritical fluids, drug delivery systems, 
intracellular pathogens 
 
1. Introduction 
The treatment of infectious diseases caused by intracellular bacteria is still a challenge for 
clinicians. Bacteria such as Mycobacterium, Legionella, Brucella or Listeria [1] have developed 
the ability to persist and replicate inside several mammalian cells including the hostile 
phagocytic cells, which constitute the first-line defense against invading pathogens. Once the 
macrophage killing mechanisms have been subverted, the intracellular habitat effectively 
protects bacteria from host defense mechanisms as well as from the action of antibiotics. Thus, 
in spite of the availability of a wide variety of in vitro active antibiotics, therapeutic failures are 
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reported, mainly because of the inability of the drugs to reach the bacteria harbouring 
intracellular compartments or to exert their activity in the intracellular environments [2]. 
Gentamicin (GEN) is an aminoglycoside antibiotic with a well-known broad spectrum of 
antibacterial activity that inhibits bacterial protein synthesis by binding to 30S subunit sites of 
the bacterial ribosome [3]. In contrast to other antibiotics that impede protein synthesis, 
aminoglycosides exhibit a concentration-dependent bactericidal activity and a post-antibiotic 
effect [4]. Due to these properties and its low cost, GEN is commonly used for initial 
antimicrobial therapy in suspected or documented bacterial septicaemia [5]. However, the 
hydrophilic nature of this antibiotic hinders its capacity to penetrate the cells and, besides, the 
internalized molecules are mainly accumulated in lysosomes, where the bioactivity of the drug is 
low. Therefore, limited intracellular activity against susceptible bacteria is often found [6, 7]. In 
this context, high and repeated doses are usually required to achieve sufficient GEN 
concentration at intracellular sites, which may induce systemic side effects such as 
nephrotoxicity and ototoxicity. These drawbacks, together with the need for parenteral 
administration, hamper its therapeutic application.   
One potential strategy to provide efficient intracellular therapy is to encapsulate GEN in 
drug delivery systems (DDS) [8, 9]. After their intravenous administration, colloidal carriers in 
the blood stream are rapidly taken up by the cells of the mononuclear phagocytic system that 
recognise these particles as foreign [10]. This characteristic, which in many cases presents a 
major obstacle, would provide great benefit in the treatment of infections that involve the 
mononuclear phagocytic system. Therefore, the use of DDS has been proposed for passive 
targeting of infected cells of the mononuclear phagocytic system to increase the therapeutic 
index of antimicrobials in the intracellular milieu, while minimizing the side effects associated 
with the systemic administration of the antibiotic.  
A number of natural and synthetic polymers have been investigated for the design of 
biodegradable particles, but, among them, poly(D,L-lactide-co-glycolide) (PLGA) has been the 
most extensively used in drug delivery. PLGA is a FDA-approved biodegradable and 
biocompatible polymer that allows the formulation of particles with versatile physicochemical 
characteristics and degradation kinetics by varying the copolymer composition and molecular 
weight [11, 12]. Recently, GEN loaded PLGA DDS have been obtained by the multiple emulsion 
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solvent evaporation method for the treatment of brucellosis [13]. The developed formulations 
were successfully captured by the macrophages and distributed mainly to the liver and spleen, 
preventing drug accumulation in kidneys [14, 15]. Moreover, GEN loaded microparticles 
significantly reduced the spleen infection. However, despite the promising results obtained, and 
in order to reduce the number of required doses, an improvement in GEN loading would be 
required before the formulation could be used for human therapy.  
To achieve this goal, GEN molecule has been modified to a more hydrophobic complex by 
hydrophobic ion pairing (HIP) with the anionic surfactant bis(2-ethylhexyl) sulfosuccinate sodium 
salt (AOT) [16]. We hypothesize that by leveraging its hydrophobicity, GEN-AOT itself may be 
formulated as a particulated material which can be captured by the infected phagocytes. 
Therefore, in this paper we describe the preparation and characterization of two novel GEN-
AOT carriers: on the one hand, PLGA GEN-AOT nanoparticles (NPs) obtained by a single 
emulsion evaporation method and, on the other, polymer-free GEN-AOT microstructured 
particles, produced by precipitation of GEN-AOT with a compressed fluid based methodology 
(Precipitation with a Compressed Antisolvent, PCA) using carbon dioxide. Particles were 
characterized in terms of size, surface charge and morphology. Moreover, encapsulation 
efficiency, drug-polymer interactions and the in vitro release of the antibiotic were also 
evaluated for polymeric NPs. Finally, the bioactivity of the developed formulations was 
assessed in vitro against Brucella melitensis as a model of facultative intracellular bacteria. 
 
2. Materials and methods 
2.1 Materials 
Bis(2-ethylhexyl) sulfosuccinate sodium salt (AOT) was supplied by Sigma (Tres Cantos, 
Spain). Carbon dioxide (purity > 99.9%) was obtained from Carburos Metálicos S.A (Barcelona, 
Spain) and acetone, HPLC grade, from Teknokroma (Sant Cugat del Vallès, Spain). PLGA 
502H (Resomer® RG 502H, PLGA 50:50, 13.7 kDa) and 752H (Resomer® RG 752H, PLGA 
75:25, 17 kDa) were purchased from Boehringer Ingelheim (Ingelheim, Germany). Gentamicin 
sulphate, polyvinyl alcohol (PVA, Mw 85000-124000, 97-99% hydrolyzed) and mannitol were 
obtained from Sigma-Aldrich (St. Louis, MO, EEUU) and ethyl acetate from Panreac Química 
S.A. (Barcelona, Spain). 
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The reagents used for fluorimetric assays were o-phtalaldehyde from Merck (Darmstad, 
Germany), β-mercaptoethanol from Sigma (St. Louis, MO, EEUU) and boric acid and diethyl 
ether from Panreac Química S.A. (Barcelona, Spain). Bacterial culture mediums, trypticase soy 
agar (TSA) and cation-adjusted Mueller-Hinton (CAMH) broth were from Biomerieux (Marcy 
l’Etoile, France) and DIFCO BD (Franklin Lakes, NJ, USA), respectively. 
 
2.2 Hydrophobic Ion Pairing of Gentamicin Sulphate  
The ionic complex of gentamicin (GEN) with the anionic surfactant bis(2-ethylhexyl) 
sulfosuccinate sodium salt (AOT), GEN-AOT, was prepared as a waxy solid by the hydrophobic 
ion pairing (HIP) method [16] according to the methodology previously described [17]. Following 
this process, 5 mol of AOT were used for the stoichiometric complexation of the 5 ionizable 
amino groups of GEN and therefore the replacement of the sulphate counter ions, yielding an 
ionic complex with a GEN:AOT ratio of 1:5. In brief, 800 ml of a solution of AOT in 
dichloromethane (12.55 mg ml-1) were added to an equal volume of a buffered aqueous solution 
(10 mM sodium acetate, 10 mM KCl, 10 mM CaCl2, pH 5.0) of GEN sulphate (4 mg ml-1) and 
stirred vigorously for 3 h. The phases were separated by centrifugation (2350 g, 5 min) and the 
ionic complex was recovered from the organic phase by evaporation and dried under vacuum 
for 15 min. 
 
2.3 Preparation of microstructured GEN-AOT by PCA 
The preparation of the polymer-free GEN-AOT microstructured particles was performed by 
a compressed fluid based technology called Precipitation with a Compressed Antisolvent (PCA) 
[18] using an experimental set-up which has previously been described [19]. The PCA-process 
scheme is depicted in figure 1. The experiments were carried out following the subsequent 
steps: first, the precipitation chamber (300 ml) was filled with CO2 and allowed to equilibrate to 
the operating pressure and temperature (10 MPa, 25 ºC). For achieving the desired molar 
fraction of CO2, xCO2 = 0.95, the back pressure valve was opened and CO2 and the organic 
solvent, acetone, were simultaneously pumped into the vessel with a volumetric CO2:solvent 
ratio of 18:1 ml min-1. After 20 min, the injection of pure organic solvent was stopped and 10 ml 
of the solution of GEN-AOT in acetone (0.3 g ml-1) were sprayed through a hollow cone nozzle 
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(diameter = 100 μm), at the same rate as the pure solvent, into the current of CO2. The 
antisolvent effect of the compressed CO2 (cCO2) on the sprayed solution caused the 
precipitation of the GEN-AOT complex. The solid particles were collected over a sintered metal 
filter covered with a PTFE membrane placed inside the autoclave. The removal of the possible 
residual solvent in the final particulate material was done by a current of CO2 at 36.67 ml min-1 
and 10 MPa for one hour. The dried particulate solid was collected from the filter after 
depressurizing the precipitation chamber. 
 
2.4 Preparation of GEN-AOT polymeric nanoparticles 
GEN-AOT was encapsulated into PLGA NPs by the oil-in-water emulsion solvent 
evaporation method using two different copolymers of PLGA, PLGA 502H and 752H. Briefly, 
different amounts of GEN-AOT were dissolved in 1 ml of ethyl acetate containing 200 mg of 
copolymer. This organic phase was emulsified with 2 ml of a 0.5% (w/v) PVA aqueous solution 
by ultrasonication (Branson sonifier 450, Branson Ultrasonics corp., Danbury, CT, USA) at 15 W 
for 1 min in ice bath. The formed O/W emulsion was then poured into a 50 ml solution of 0.2% 
(w/v) PVA and continuously stirred for at least 3 h at room temperature to allow solvent 
evaporation and NP formation. Particles were collected by centrifugation (24,000 g, 15 min) 
(Sigma Laboratory Centrifuges, 3K30, Rotor No. 12150-H, Osterode am Harz, Germany), 
washed three times with ultrapure water and freeze dried after addition of 5% mannitol as a 
cryoprotector. Each formulation was produced at least in triplicate. 
 
2.5 Physicochemical Characterization of polymeric nanoparticles and PCA-processed GEN-
AOT 
2.5.1 Particle size and zeta potential measurement 
NPs size was determined by a dynamic light scattering technique using a Zetasizer Nano 
ZS analyser system (Malvern Instruments, Worcestershire, UK). Formulations were diluted in 
ultrapure water and measured in triplicate. The results were expressed as the average of the 
three measurements. The polydispersity index (PdI), which indicates the width of the size 
distribution, was also obtained. 
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Surface charge or zeta potential values of the formulations were determined by Laser 
Doppler Electrophoresis using the same apparatus. Samples were prepared by diluting the 
particle suspensions in ultrapure water. Measurements were performed in triplicate and each 
measurement was averaged over at least 12 runs. 
 
2.5.2 Particle morphology and gentamicin distribution 
The morphology of PLGA GEN-AOT NPs was studied using a field emission scanning 
electron microscope Quanta 200 FEG-SEM (FEI, Eindhoven, The Netherlands) and the 
morphology of raw and PCA-processed GEN-AOT was analyzed using a JEOL JSM-6300 (Jeol 
LTD, Tokio, Japan). The samples were directly mounted on a bioadhesive carbon sheet and 
coated with gold for 4 minutes using a sputter coater (K550x, Emitech, Ashford, UK). To study 
the GEN-AOT distribution in the polymeric matrices Energy Dispersive X-ray (EDX) 
microanalyses were performed using Quanta 200 FEG-SEM, (FEI, Eindhoven, The 
Netherlands) equipped with an EDX system for chemical analysis (EDAX, Tiburg, The 
Netherlands). Images were analyzed with EDEX Genesis software. For the EDX study the 
samples were coated with carbon using a K550 coater with a K250 carbon coating attachment 
(Emitech, Ashford, UK). 
 
2.5.3 Residual PVA 
The amount of surface-associated PVA was determined by a colorimetric method based on 
the formation of a complex between two adjacent hydroxyl groups of PVA and a molecule of 
iodide [20]. Briefly, 2 ml of 0.5 M NaOH were added to 2 mg of freeze-dried NPs and incubated 
for 15 minutes at 60ºC. Then the solution was neutralized with 900 μl of 1 N HCl and adjusted to 
5 ml with deionised water. Subsequently, 3 ml of 0.65 M boric acid, 0.5 ml of 0.05 M/0.15 M I2/KI 
and 1.5 ml of distilled water were added to each sample. Finally, after 15 minutes of incubation 
at room temperature, the absorbance of the resulting solution was measured at 690 nm using 
an Agilent 8453 UV-Vis spectrophotometer (Agilent Technologies, Waldbronn, Germany). In 
parallel, a calibration curve of PVA standard solutions was prepared following the same 
procedure. 
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2.5.4 X-ray powder diffraction analyses (XRPD) 
Diffraction patterns were recorded on a Siemens D5000 powder diffractometer (Bragg-
Brentano geometry) using Cu Kα radiation (λ = 1.5406 Å), at a voltage of 40 kV and an intensity 
of 35 mA. Samples were mounted on a flat sample holder and were scanned from 2.5º to 100º 
in 2θ, at a scan rate of 0.02° 2θ s−1. 
 
2.5.5 Fourier transform infrared spectroscopy (FTIR) 
FTIR analyses were carried out using a Spectrum One (Perkin Elmer, USA) spectrometer 
attached to an attenuated total reflectance accessory (UATR accessory, Perkin Elmer, USA). 
Powder samples were directly placed on the diamond disk and scanned over the range from 
4000 cm-1 to 650 cm-1 at a resolution of 1 cm-1. Each spectrum was recorded by averaging 4 
scans. 
 
2.6 Drug loading and encapsulation efficiency 
The amount of encapsulated GEN was determined by fluorimetry after the extraction of the 
antibiotic from the NP and its derivation with o-phthalaldehyde [21]. Briefly, 5-10 mg of 
accurately weighted formulations were dispersed in 1 ml of a 0.1 M NaOH solution and stirred 
for 5 h to hydrolyse the polymer. Samples were centrifuged twice (45,000 g, 15 min and 21,000 
g, 10 min) to eliminate the traces of polymer and supernatants were collected. To quantify the 
GEN, supernatants were diluted in 0.4 M boric acid pH 9.7 and 50 μl were placed in a 96-well 
microplate (TPP, Trasadingen, Switzerland). Then 50μl of fluorimetric assay solution [0.04% 
(w/v) o-phthalaldehyde, 0.1% (v/v) diethyl ether, 0.2% (v/v) β-mercaptoethanol in boric acid] 
were added to the samples and fluorescence was measured in a Tecan GENios fluorimeter 
(Tecan Group Ltd, Maennedorf, Switzerland) (excitation wavelength 340 nm, emission 
wavelength 450 nm). GEN content was determined by extrapolating the fluorescence values 
from a calibration curve prepared with standard GEN-AOT solutions in boric acid 0.4 M pH 9.7. 
Finally, the encapsulation efficiency (%) of the drug, described as the percentage of determined 
loading relative to the nominal (theoretical) loading, was calculated. 
 
2.7 In vitro drug release from nanoparticles 
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GEN-AOT release profile from the NPs was determined by dispersing the formulations (5-
10 mg accurately weighted) in 1.5 ml of phosphate buffered saline (PBS) pH 7.4 with 0.02% 
(w/v) sodium azide used as a bacteriostatic agent. Samples were incubated at 37 ºC under 
orbital shaking in a rotatory plate (FALC F200, Falc intruments, Treviglio, Italy) for 10 weeks. At 
appropriate intervals, the tubes were centrifuged (21,000 g, 10 min), supernatant was collected 
and replaced with fresh release medium to continue the study. The collected supernatants were 
centrifuged again and the resulting particle-free solutions were fluorometrically analyzed for 
drug content as described above. The amount of antibiotic released in the first 24 h is here 
defined as the burst effect. Results are presented as the percentage of released antibiotic with 
regard to the amount of GEN encapsulation.  
 
2.8 In vitro biological activity studies  
Brucella melitensis 16M (ATCC 23456, biotype 1) smooth virulent strain and Escherichia 
coli (ATCC 25922) were used for the microbiological studies. B. melitensis was used as a model 
of facultative intracellular bacteria, and actvity against E. coli was determined as quality control. 
Experiments were performed with fresh bacteria previously incubated on TSA plates at 37 ºC for 
48 h or 24 h, respectively. 
Minimum inhibitory (MIC) and bactericidal (MBC) concentration of GEN-AOT formulations 
were determined by broth microdilution method using CAMH broth. Antibiotic stock solutions 
corresponding to equivalent concentration of 1.28 mg GEN ml-1 were prepared in 0.9% saline 
solution and further diluted 1:10 in CAMH broth. Bacterial suspension was prepared by 
transferring three isolated colonies from a TSA plate into a 0.9% saline solution and adjusted to 
an optical density of 0.125 (600 nm) (~108 CFU ml-1). Suspension was diluted 1:100 in CAMH 
broth to a concentration of 106 CFU ml-1 and the real inoculum was determined by plating 
appropriate dilutions on TSA plates. Finally, 100 µl of each treatment was double-serially diluted 
in 96-well microplates and mixed with a 100 µl aliquot of the bacterial suspension, which 
resulted in a starting inoculum of 5 x 105 CFU ml-1 and final GEN concentrations ranging from 
0.06 to 64 mg ml-1. As a control for bacterial growth, antibiotic-free medium was also included. 
After incubation at 37 °C for 48 h, MICs were defined as the lowest concentration of drug that 
resulted in no visible bacterial growth. Subsequently, 20 µl were removed from wells without 
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visual growth and plated on TSA plates for colony counting. MBCs were determined from those 
plates after 4-5 days incubation at 37 °C as the minimum concentration of formulation that 
yielded 99.9% killing of bacteria. 
In these assays, empty PLGA NPs and AOT alone were also included as controls in order 
to study if the activity of the different treatments was neatly attributable to the GEN fraction. 
 
3. Results and discussion 
3.1 Microstructuring of GEN-AOT by PCA 
One possible approach to improve the bioavailability of poorly water-soluble drugs, such 
the GEN-AOT complex, is to enhance their dissolution rate and biodistribution by increasing 
their accessible area through micronization processes [22]. In this context, we have used a 
compressed fluid based method (PCA) for the processing of GEN-AOT. Figure 2 depicts the 
scanning electron microscopy (SEM) images of the non-processed and PCA-precipitated GEN-
AOT together with two photographs showing the appearance of the same mass of antibiotic 
before and after processing. The macroscopic aspect of the solid was dramatically modified by 
PCA, being changed from yellowish waxy flakes to a white powdered solid. As can be observed 
in figure 2, the volume occupied by the same mass of PCA-GEN-AOT is much higher than that 
of the non-processed complex, implying a density decrease upon PCA-precipitation. This 
change is also noticeable at microscopic scale, since the SEM images of the processed and 
non-processed GEN-AOT show a great change in the microstructure of the antibiotic complex. 
Already obvious at low magnification, the surface of the particles obtained by PCA presents a 
much higher roughness than that of the non-processed GEN-AOT. Indeed, whilst the raw 
complex possesses a completely smooth surface, that of PCA-GEN-AOT is formed by 
homogeneous networked micron-sized particles that abruptly increase its accessible area. This 
higher surface area could improve the dispersion and interaction of the hydrophobic PCA-
complex with the infected cells in comparison with the non-processed GEN-AOT.  
 
3.2 Characterization of GEN-AOT polymeric nanoparticles 
The success of a DDS based intracellular therapy depends on the efficient internalization 
and drug release of the carrier inside the target cells. It is well known that the interaction 
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between DDS and phagocytic cells and the subsequent particle uptake are largely affected by 
particle size and surface properties such as charge and hydrophobicity [23, 24]. The main 
physicochemical characteristics of the developed nanoparticle formulations are summarized in 
table 1. 
 
3.2.1 Particle size and zeta potential 
Encapsulation of GEN-AOT by the emulsion solvent evaporation method yielded NPs with 
mean diameters in the range 250-330 nm and polydispersity indexes below 0.25, which 
indicates that NPs with narrow size distribution were obtained. Low micrometer and nanometer 
size particles have been reported to be efficiently cleared by the phagocytic cells [12], so 
adequate size particles for targeting intracellular sites were obtained.   
It was observed that the particle size of the most loaded NPs in PLGA 752H (NP6) is 
slightly higher than that of the less loaded particles (NP4), probably due to both the increase in 
the organic phase viscosity and the expansion of the nanoparticle matrix at these high drug 
loadings. In the case of PLGA 502H NPs, the increase in particle size is within the 
measurement deviation and no significant particle size increase was observed.   
All the formulations exhibited negative surface charge, which was attributed to the 
uncapped carboxylic end groups of the copolymers. However, it was noteworthy that zeta 
potential increased when GEN-AOT was incorporated into the formulations, bringing it close to 
neutrality. Since it has been found that zeta potential of GEN-AOT particles suspended in 
ultrapure water is around -1 mV, it could be deduced that the increase in the surface charge 
was due to the presence of drug located on the NP surface. This behaviour may be attributed to 
the surfactant properties of the AOT molecules, which could situate some of the drug at the 
boundary layer between the water phase and the organic phase during particle formation. As a 
result, NPs with a more hydrophobic surface are obtained, which will promote hydrophobic 
interactions between NPs and cell membranes and hence enhanced NP uptake [25-27]. The 
role of the surface hydrophobicity has also been studied in nature for intracellular 
microorganisms such as Mycobacterium [28], Chlamydia [29, 30] or Brucella [31], where 
hydrophobic components of the membranes have been found to play an important role in the 
attachment of the pathogens to the host cells. 
 11
 3.2.2 Morphology and gentamicin distribution of the nanoparticles 
The SEM images taken of the different formulations (figure 3, NP1 to NP6) reveal that 
homogeneous NPs are obtained by the oil in the water single emulsion solvent evaporation 
method. No significant increase in particle size is observed upon augmenting the content of 
GEN-AOT in the NP formulation. However, a decrease is observed in sphericity for NPs with the 
highest drug content, as was also observed in Elizondo et al [17]. Spherical particles tend to 
coalesce and form micro/nano-aggregates upon increasing the antibiotic content in the 
polymeric NPs. Thus, there is an obvious difference in shape and surface morphology between 
NPs with low and high loading.  
EDX microanalysis was performed in order to confirm whether the oil in water single 
emulsion solvent evaporation method is able to produce NPs with homogeneous distribution of 
the antibiotic. EDX technique enables us to obtain not only the presence but also the spatial 
disposition of the elements forming a solid sample, and is therefore useful for studying the 
spatial distribution of GEN-AOT, which can be distinguished from PLGA by its S atoms. The 
EDX maps of sulphur (S), present in the antibiotic, and oxygen (O), present in both, polymer 
and antibiotic, of a physical mixture of pure GEN-AOT and pure PLGA 752H (Figure 4, PM) 
have been depicted as a control sample, in which antibiotic and polymer particles are clearly 
distinguishable by the presence or absence of signal in the S map, respectively. EDX maps of 
the most loaded PLGA 752H NPs are also shown in figure 4 (NP 6). The sulphur map of the NP 
6 shows clearly that all particles contain sulphur, even though the intensity is not so high due to 
the light nature of the element. Therefore GEN-AOT is distributed across all the NPs, indicating 
that the emulsion technique provided a homogeneous entrapment of the antibiotic.  
 
3.2.3 Residual PVA content 
The percentage of residual PVA was found to be less than 4% (w/w) for all formulations 
(table 1). PVA is one of the most commonly used stabilizers in the production of polymeric NP 
such as PLGA NP. When dissolved, it forms a viscous solution that strongly adsorbs around the 
emulsion and drops during the emulsification process. It has been demonstrated that despite 
several washings a certain amount of PVA remains associated with the PLGA NPs surface [32, 
 12
33], which can affect their physical and cellular uptake properties [20]. However, in this case 
very low residual PVA values were obtained. 
 
3.2.4 Cristallinity of GEN-AOT 
In order to gather structural information about the polymeric NPs, powder X-ray diffraction 
patterns of the different species were measured; these are depicted in figure 5. Even though 
GEN-AOT could not be claimed to be a crystalline compound, its powder diffraction pattern 
shows a unique reflection at 3.6 degrees indicating a certain long-range order of this molecule. 
This type of powder X-ray diffraction pattern is typically observed for liquid crystals in which the 
periodicity has been partially lost and only a few peaks, or rather an intense peak at low angles, 
is shown [34]. Upon formation of the NPs, this reflection is maintained at 3.6 degrees and its 
intensity increases with respect to the amorphous halo of the polymers when the content of 
antibiotic in the NPs augments. These facts indicate that the integration of GEN-AOT in the 
polymeric matrix does not modify its structure. 
In contrast, the powder X-ray diffraction patterns of pure polymers PLGA 502H and PLGA 
752H (figures 5A and 5B, respectively) show the typical halo of amorphous phase. 
The X-ray powder diffraction pattern of the PVA is also represented. It shows several 
reflections in the range from 10 to 45 in 2θ which implies that the compound has low 
crystallinity. These reflections are not present in the X-ray powder diffraction patterns of the 
NPs, confirming the low % of PVA remaining in the NPs formulation. 
 
3.2.5 Drug-polymer interactions by Fourier transform infrared spectroscopy 
The FTIR spectra of the pure polymers, pure GEN-AOT and the polymeric NPs are 
displayed in figures 6A (PLGA 502H) and 6B (PLGA 752H). The assignation of vibration bands 
attributed to GEN-AOT is described elsewhere and corresponds basically to the bands 
associated with the vibrations of the surfactant AOT [17]. Thus, bands between 3000 and 2800 
cm-1 are attributed to alkyl chain vibrations of the surfactant chains (not shown in the figure), 
bands at 1734, 1201 and 1157 cm-1 are attributed to the AOT ester group and finally the band at 
1036 cm-1 is attributed to the SO32- group. Regarding the polymers, the more significant bands 
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are those assigned to the ester groups at 1748, 1165 and 1085 cm-1 for PLGA 502H and at 
1750, 1184 and 1085 cm-1 for PLGA 752H.  
Although the FTIR bands corresponding to the polymers overlap with those of the antibiotic 
complex, the presence of the most significant band of GEN-AOT (1036 cm-1), whose intensity 
increases upon augmenting its content in the formulations, is observed in the FTIR spectra of 
the antibiotic loaded NPs. Neither appreciable shifts nor disappearance or appearance of new 
bands are observed, the NPs spectra being the result of superimposing those of the pure PLGA 
and GEN-AOT, which would indicate the absence of significant drug:polymer interactions in the 
solid state. 
 
3.3 GEN-AOT encapsulation efficiency 
Ion pairing strategy is the object of growing interest for preparing highly loaded DDS 
containing water soluble drugs and proteins [35, 36]. HIP makes it possible to increase active 
compounds’ solubility in organic solvents [16, 37], thereby permitting us to encapsulate them in 
water insoluble polymers like PLGA by a single emulsion method and preventing the diffusion 
escape of the drugs to the aqueous phase. The hydrophobic modification of GEN enabled us to 
prepare PLGA nanoparticles with very high drug entrapment efficiencies. As table 2 shows, 
nearly 100% of the GEN-AOT complex was encapsulated into the formulations and GEN 
loadings as high as 60 µg/mg NP were obtained. Interestingly, encapsulation efficiency was 
maintained when the drug nominal loading increased, indicating that a saturation of the organic 
phase had not been reached. Thus, the addition of the AOT groups to GEN successfully 
improved the antibiotic payload of the carriers to concentrations not reached before for GEN 
containing PLGA micro or nanoparticles [13, 38]. This is an important achievement, since 
eradication of intracellular microorganisms requires high drug concentrations inside the infected 
cells [2]. Moreover, obtaining highly loaded DDS will reduce the quantity of particles to be 
administered to achieve the desired dose of antibiotic, which, in turn, have positive effects on 
the toxicity and cost of the treatment.
 
3.4 In vitro drug release studies 
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GEN release profile from the carriers was investigated by incubating the formulations in 
PBS (pH 7.4) at 37 ºC. Release profile of GEN exhibited a biphasic pattern characterized by an 
initial burst during the first 24 h, in which the release might be attributed to the presence of non-
entrapped antibiotic adsorbed on the surface of the NPs, followed by a slow sustained release 
for up to 10 weeks (figure 7). GEN release pattern of NP 1 formulation differs from the other 
nanoparticles’ formulation. In this case, the hydrophilicity of the formulation may favour faster 
solubilisation and erosion of the polymeric matrix, instead of the more progressive degradation 
occurring in the more hydrophobic formulations, which results in a secondary burst. 
In contrast to previous studies where high burst releases were reported for GEN loaded 
carriers [10], burst was moderate for all the GEN-AOT formulations, concretely, less than 12%. 
This reduction in the initial burst release was attributed to the hydrophobic ion pairing of GEN 
with the AOT surfactant and its consequent enhanced hydrophobicity, which may allow an 
increased retention of the drug on the NP surface. The low solubility of the GEN-AOT complex 
in aqueous environments could also result in a slow diffusion of the drug through the polymeric 
matrix and, therefore, in a more sustained release kinetic of the drug. Similar release profiles 
have also been reported for other ion-paired drugs and proteins [16, 35, 39]. 
The comparison between the release profiles of the different developed PLGA carriers 
revealed that the release of GEN from the particles was highly influenced by the used 
copolymer type and drug loading. Figures 7A and 7B illustrate the in vitro release profiles of the 
drug from the different formulations made with PLGA 502H and 752H respectively. Drug release 
from 502H NPs was faster than from 752H NPs, which can be explained by the different 
monomer composition of the two PLGA copolymers. The higher content of hydrophilic glycolic 
units of the 502H copolymer contributes to its faster degradation and consequently to the faster 
release of the encapsulated drug from the carriers [40]. Thus, by the end of the study, 502H 
NPs released between 71 and 100% of their drug content while only 55-67% of the drug was 
released from 752H NPs. 
In order to analyze the influence of the drug loading on the release properties of the 
formulations, the release profiles of PLGA 502H and 752H NPs containing different amounts of 
drug loading were studied. Interestingly, it was found that increasing the amount of GEN in the 
formulation decreased the drug release rate. 502H NPs with a nominal loading of 20 mg 
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released all their content in 70 days, whereas the same NPs but prepared with 40 and 60 mg of 
GEN-AOT released 87 and 70% of their drug loading, respectively. By the same time, 20 mg, 
40 mg and 60 mg loaded 752H NPs released 67, 61 and 55% of the drug. This result is in 
accordance with those observed by other authors who found that, since the drug loading did not 
affect significantly the particle size, and who attributed this trend to the formation of a more 
hydrophobic and compact internal structure of the NPs that hinder the penetration of the water 
[41]. In addition, NP coalescence could reduce drug delivery rates due to a decrease in 
accessible surface which could be translated into delayed release profiles for the most loaded 
NPs. Finally, it should also be taken into consideration that the use of in vitro release models 
presents limitations with respect to other physicochemical conditions. For example, the Cation 
adjusted Mueller Hinton broth used for in vitro activity studies contains nitrogenous compounds, 
vitamins, carbon, sulphur and amino acids, compounds not present in PBS. Thus, we may 
expect different behaviour in PBS with respect to the more complex bacterial culture medium 
used in the bioassay, which probably resulted in faster release of the antibiotic. 
Overall, the obtained results reveal a significant improved controlled release of GEN over 
the previously reported PLGA micro and nanoparticles which ensures that the complete payload 
of the NP will be taken up by the cells. 
 
3.5 Antimicrobial activity of free and encapsulated GEN-AOT 
For therapeutic drugs, retention of biological activity is a big issue, since instability 
(chemical modification, denaturation) may occur in the manufacturing process as well as during 
the release.  
The activity of the new GEN-AOT formulations was studied against Brucella melitensis, 
determining the minimal inhibitory and bactericidal concentrations. The obtained results are 
summarized in table 3. MICs against the quality control bacteria E. coli ATCC 25922 were within 
the reference range (0.5 mg ml-1). MICs of the different forms of GEN-AOT against B. melitensis 
were one double-dilution above or below the MIC of the reference compound GEN sulphate. 
These results demonstrate that the antibiotic activity of GEN was maintained irrespective of 
AOT coupling, processing by PCA and encapsulation in the different PLGA NPs. Moreover, 
since empty PLGA NPs and AOT alone did not show activity against the bacterial inoculum 
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(above 64 mg ml-1 and 32 mg ml-1, respectively), the activity of the different treatments was 
neatly attributable to the GEN fraction. Finally, the MBC values proved similar to MICs for all the 
treatments, confirming that the biological activity of GEN was preserved. Thus, on the basis of 
these findings, GEN-AOT particulate carriers appear to be promising therapeutic tools in the 
treatment of susceptible intracellular bacterial infections. Further studies will focus on the 
cellular toxicity and efficacy of the developed formulations in Brucella infected animal models.   
 
4. Conclusions 
Ion pairing of gentamicin with the non-ionic AOT surfactant allowed its micronization by 
PCA, obtaining a particulated material with a high surface area and its encapsulation in 
polymeric NPs by the simple emulsion solvent evaporation method. This latter procedure 
provided NPs with GEN-AOT encapsulation efficiency around 100% and sustained release of 
the drug over 10 weeks. Moreover, neither ion pairing, supercritical fluid processing nor 
encapsulation in polymeric NPs affected the bactericidal activity of gentamicin. This fact, 
together with the higher nominal loading obtained by using the anionic AOT surfactant, supports 
the benefits which such formulations offer for treating susceptible intracellular bacterial 
infections. 
 
Acknowledgments 
This work was supported by DGI Spain under projects NANOFAR (NAN2004-09159-C04), 
EMOCIONA (CTQ2006-06333/BQU) and POMAS (CTQ-2010-19501). E. Imbuluzqueta thanks 
the Spanish Ministerio de Educación (programa FPU) for the fellowship grant. We acknowledge 
financial support from Instituto de Salud Carlos III, through “Acciones CIBER”. The authors 
thank Judith Oró and Ana Esther Carrillo for the technical support in taking SEM and EDX 
images and MATGAS personnel for the technical assessment with the high pressure 
equipments. E. Elizondo thanks Consejo Superior de Investigaciones Científicas (CSIC) for her 
PhD bursary. N. Ventosa thanks Banco de Santander for the Chair of Knowledge and 
Technology Transfer Parc de Recerca UAB-Santander. We also thank TECNIO network for 
financial support on technological transfer activities related to this work. 
 
 17
References 
[1] Haas, A. The Phagosome: Compartment with a License to Kill. Traffic 2007;8:311-330. 
[2] Carryn S, Chanteux H, Seral C, Mingeot-Leclercq MP, Van Bambeke F, Tulkens PM. 
Intracellular pharmacodynamics of antibiotics. Infect Dis Clin North Am 2003;17:615-634. 
[3] Davis BD. Mechanism of bactericidal action of aminoglycosides. Microbiol Rev 1987;51:341-
350. 
[4] Zhanel GG, Craig WA. Pharmacokinetic contributions to postantibiotic effects. Focus on 
aminoglycosides. Clin Pharmacokinet 1994;27:377-392. 
[5] Durante-Mangoni E, Grammatikos A, Utili R, Falagas ME. Do we still need the 
aminoglycosides? Int J Antimicrob Agents 2009;33:201-205. 
[6] Carryn S, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. Comparative intracellular 
(THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and 
fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations. 
Antimicrob Agents Chemother 2002;46:2095-2103. 
[7] Seral C, Van Bambeke F, Tulkens PM. Quantitative analysis of gentamicin, azithromycin, 
telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against 
intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob Agents 
Chemother 2003;47:2283-2292. 
[8] Gamazo C, Prior S, Lecaroz MC, Vitas AI, Campanero MA, Perez G, et al. Biodegradable 
gentamicin delivery systems for parenteral use for the treatment of intracellular bacterial 
infections. Expert Opin Drug Deliv 2007;4:677-688. 
[9] Ranjan A, Pothayee N, Seleem MN, Tyler RD, Jr., Brenseke B, Sriranganathan N, et al. 
Antibacterial efficacy of core-shell nanostructures encapsulating gentamicin against an in vivo 
intracellular Salmonella model. Int J Nanomedicine 2009;4:289-297. 
[10] Owens III DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of 
polymeric nanoparticles. Int J Pharm 2006;307:93-102. 
[11] Ravi S, Peh KK, Darwis Y, Murthy BK, Singh TR, Mallikarjun C. Development and 
characterization of polymeric microspheres for controlled release protein loaded drug delivery 
system. Indian J Pharm Sci 2008;70:303-309. 
 18
[12] Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA 
microspheres. Adv Drug Deliv Rev 1997;28:5-24. 
[13] Lecaroz C, Gamazo C, Renedo MJ, Blanco-Prieto MJ. Biodegradable micro- and 
nanoparticles as long-term delivery vehicles for gentamicin. J Microencapsul 2006;23:782-792. 
[14] Lecaroz MC, Blanco-Prieto MJ, Campanero MA, Salman H, Gamazo C. Poly(D,L-lactide-
coglycolide) particles containing gentamicin: pharmacokinetics and pharmacodynamics in 
Brucella melitensis-infected mice. Antimicrob Agents Chemother 2007;51:1185-1190. 
[15] Lecaroz C, Blanco-Prieto MJ, Burrell MA, Gamazo C. Intracellular killing of Brucella 
melitensis in human macrophages with microsphere-encapsulated gentamicin. J Antimicrob 
Chemother 2006;58:549-556. 
[16] Falk R, Randolph TW, Meyer JD, Kelly RM, Manning MC. Controlled release of ionic 
compounds from poly (L-lactide) microspheres produced by precipitation with a compressed 
antisolvent. Journal of Controlled Release 1997;44:77-85. 
[17] Elizondo E, Sala S, Imbuluzqueta E, González D, Blanco-Prieto MJ, Gamazo C, Ventosa 
N, Veciana J. High loading of gentamicin in bioadhesive PVM/MA nanostructured microparticles 
using compressed carbon-dioxide. Pharm Res 2010; In press, (DOI 10.1007/s11095-010-0248-
x). 
[18] Dixon DJ, Johnston KP, Bodmeier RA. Polymeric materials formed by Precipitation with a 
Compressed Fluid Antisolvent. ALChE J 1993;39:127-139. 
[19] Gimeno M, Ventosa N, Boumghar Y, Fournier J, Boucher I, Veciana J. Micronization of the 
chitosan derivatives D-glucosamine hydrochloride and D-glucosamine sulphate salts by dense 
gas anti-solvent precipitation techniques. J Supercrit Fluids 2006;38:94-102. 
[20] Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl alcohol associated 
with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular 
uptake. J Control Release 2002;82:105-114. 
[21] Benson JR, Hare PE. O-phthalaldehyde: fluorogenic detection of primary amines in the 
picomole range. Comparison with fluorescamine and ninhydrin. Proc Natl Acad Sci U S A 
1975;72:619-622. 
[22] Fahr A, Liu X. Drug delivery strategies for poorly water-soluble drugs. Expert Opin Drug 
Deliv 2007;4:403-416. 
 19
[23] Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. Targeting to macrophages: role of 
physicochemical properties of particulate carriers-liposomes and microspheres-on the 
phagocytosis by macrophages. J Control Release 2002;79:29-40. 
[24] Tabata Y, Ikada Y. Macrophage phagocytosis of biodegradable microspheres composed of 
L-lactic acid/glycolic acid homo- and copolymers. J Biomed Mater Res 1988;22:837-858. 
[25] Torche AM, Le Corre P, Albina E, Jestin A, Le Verge R. PLGA microspheres phagocytosis 
by pig alveolar macrophages: influence of poly(vinyl alcohol) concentration, nature of loaded-
protein and copolymer nature. J Drug Target 2000;7:343-354. 
[26] Nam HY, Kwon SM, Chung H, Lee SY, Kwon SH, Jeon H, et al. Cellular uptake mechanism 
and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. J Control 
Release 2009;135:259-267. 
[27] Prior S, Gander B, Blarer N, Merkle HP, Subira ML, Irache JM, et al. In vitro phagocytosis 
and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) 
microspheres. Eur J Pharm Sci 2002;15:197-207. 
[28] Saito H, Tomioka H, Watanabe T, Sato K. Mechanisms of phagocytosis of Mycobacterium 
leprae and other mycobacteria by human oligodendroglial cells. Infect Immun 1986;51:163-167. 
[29] Basovskiy YI, Shkarupeta MM, Levitskiy SA, Kostryukova ES, Lazarev VN, Govorun VM. 
Hydrophobic domains determine localization of IncC and IncG full-length proteins of C. 
trachomatis during their expression in cultured HeLa cells. Bull Exp Biol Med 2008;145:425-429. 
[30] Su H, Watkins NG, Zhang YX, Caldwell HD. Chlamydia trachomatis-host cell interactions: 
role of the chlamydial major outer membrane protein as an adhesin. Infect Immun 
1990;58:1017-1025. 
[31] Cardoso PG, Macedo GC, Azevedo V, Oliveira SC. Brucella spp noncanonical LPS: 
structure, biosynthesis, and interaction with host immune system. Microb Cell Fact 2006;5:13-
22. 
[32] Scholes PD, Coombes AG, Illum L, Davis SS, Watts JF, Ustariz C, et al. Detection and 
determination of surface levels of poloxamer and PVA surfactant on biodegradable 
nanospheres using SSIMS and XPS. J Control Release 1999;59:261-278. 
 20
[33] Shakesheff KM, Evora C, Soriano II, Langer R. The Adsorption of Poly(vinyl alcohol) to 
Biodegradable Microparticles Studied by X-Ray Photoelectron Spectroscopy (XPS). J Colloid 
Interface Sci 1997;185:538-547. 
[34] Mindyyuk OY, Stetzer MR, Heiney PA, Nelson JC, Moore JS. High resolution X-ray 
diffraction study of a tubular liquid crystal. Adv Mater 1998;10:1363-1366. 
[35] Dalwadi G, Sunderland B. An ion pairing approach to increase the loading of hydrophilic 
and lipophilic drugs into PEGylated PLGA nanoparticles. Eur J Pharm Biopharm 2009;71:231-
242. 
[36] Yang L, Cui F, Shi K, Cun D, Wang R. Design of High Payload PLGA Nanoparticles 
Containing Melittin/Sodium Dodecyl Sulfate Complex by the Hydrophobic Ion-Pairing 
Technique. Drug Dev Ind Pharm 2009;1-9. 
[37] Meyer JD, Manning MC. Hydrophobic ion pairing: altering the solubility properties of 
biomolecules. Pharm Res 1998;15:188-193. 
[38] Lecaroz C, Gamazo C, Blanco-Prieto MJ. Nanocarriers with gentamicin to treat intracellular 
pathogens. J Nanosci Nanotechnol 2006;6:3296-3302. 
[39] Choi SH, Park TG. Hydrophobic ion pair formation between leuprolide and sodium oleate 
for sustained release from biodegradable polymeric microspheres. Int J Pharm 2000;203:193-
202. 
[40] Lu L, Garcia CA, Mikos AG. In vitro degradation of thin poly(DL-lactic-co-glycolic acid) films. 
J Biomed Mater Res 1999;46:236-244. 
[41] Mu L, Feng SS. PLGA/TPGS nanoparticles for controlled release of paclitaxel: effects of 
the emulsifier and drug loading ratio. Pharm Res 2003;20:1864-1872. 
 21
Figure legends: 
Figure 1. Schematic illustration of the PCA process used for the precipitation of gentamicin-
AOT. 
 
Figure 2. SEM images of gentamicin-AOT before (left) and after (right) being processed by 
PCA. Inset: photograph of the same mass of gentamicin-AOT before (left) and after (right) its 
processing. 
 
Figure 3. SEM micrographs at a magnification x40,000 of gentamicin-AOT PLGA 502H (NP 1 to 
NP 3) and 752H (NP 4 to NP 6) with different initial drug loadings, 20 mg (NP 1 and NP 4), 40 
mg (NP 2 and NP 5) and 60 mg (NP 3 and NP 6) of gentamicin-AOT. 
 
Figure 4. EDX images of most loaded gentamicin AOT PLGA 752H nanoparticles (NP 6) and a 
physical mixture (PM) of gentamicin-AOT and PLGA 752H. SEM image (left), sulphur map 
(middle) and oxygen map (right). 
 
Figure 5. XRPD patterns of PVA tensoactive, gentamicin-AOT, pure PLGA polymers and 
polymeric nanoparticles; PLGA 502H and gentamicin-AOT loaded PLGA 502H nanoparticles 
(A) and PLGA 752H and gentamicin-AOT loaded PLGA 752H nanoparticles (B).  
 
Figure 6. FTIR spectra of gentamicin-AOT, pure PLGA 502H and nanoparticles NP 1 to NP 3 
(A) and pure PLGA 752H and nanoparticles NP 4 to NP 6 (B). 
 
Figure 7. Gentamicin release profile from PLGA 502H (A) and PLGA 752H (B) NP in phosphate 
buffered saline (pH 7.4) as a function of the nominal drug loading. Data are expressed as mean 
± SD, n=3.  
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